The study, in a rat model induced by STZ and a high-fat diet, seeks to assess whether the combined therapy of a SIRT1 direct activator along with a SIRT1 stabilizer can offer an approach to alleviate the pathophysiological features of metabolic syndrome, including insulin resistance, oxidative stress, inflammation, dyslipidemia, and hepatic lipid accumulation. The gene discussed is SIRT1; the disease is Insulin resistance.